31 research outputs found
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
BACKGROUND: Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10–50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma. METHODS: Patients with stages Ia or Ib, Grade 2 or 3 and Ic to IIb (any grade) were included. Patients were treated with 4 cycles of Paclitaxel 175 mg/m(2 )and Carboplatin [area under the curve (AUC) 6 (Calvert Formula)] every 3 weeks. RESULTS: Sixty-nine patients with no residual disease following cytoreductive surgery and minimal or modified surgical staging were included in this analysis. Grade 3 or 4 neutropenia occured in 29.9% of patients, while neutropenic fever was reported in 4.5%. Neurotoxicity (all Grade 1 or 2) was reported in 50% of cases. Median follow-up was 62 months. 5-year overall survival (OS) and relapse-free survival (RFS) were: 87% (95% confidence intervals [CI]: 78–96) and 79% (95% CI: 69–89), respectively. Significantly fewer patients with stages Ic-IIb and tumor grade 2 or 3 achieved a 5-year RFS than patients with only one of these two factors (73% vs 92%, p = 0.03). CONCLUSION: Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma. Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from more extensive treatment
Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group
Objectives: Stage I testicular nonseminomatous germ-cell tumors (NSGCT) are highly curable. Following orchidectomy surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection can be applied. Certain factors are used to select patients in high-risk for relapse. We report the outcome and safety of a risk-adapted strategy by the Hellenic Cooperative Oncology Group. Methods: Between 1994 and 2004, 142 patients with stage I NSGCT and 1 of the following risk factors: lymphovascular invasion (LVI), invasion of tunica vaginalis, spermatic cord, rete testis or scrotal wall, embryonal component >50% of the total tumor, were prospectively included in a protocol of adjuvant chemotherapy consisting of two 3-week courses of bleomycin 15 IU, etoposide 120 mg/m2, and cisplatin 40 mg/m2 for 3 consecutive days with G-CSF support. Results: Median follow-up was 79 months and 138 patients have been followed for at least 2 years. Seventy-seven patients (54%) had LVI and 74 (52%) had >50% embryonal component. There was 1 relapse, which was cured with chemotherapy and surgery. Another patient died due to disease-unrelated causes and 1 patient developed a new primary of the remaining testicle, which was cured with surgery. Conclusion: Two cycles of bleomycin/etoposide/cisplatin is an effective and safe form of adjuvant therapy in high-risk stage I NSGCT. © 2011 Elsevier Inc
Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study
Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group Study
Salvage therapy in heavily pretreated ovarian cancer with single agent pegylated liposomal doxorubicin (PLD): Preliminary results of a multicenter phase II study of the Hellenic Co-Operative Oncology Group.
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study
Objective. Taxanes, anthracyclines, and platinum compounds represent the
chemotherapeutic agents with the greatest activity in metastatic
endometrial carcinoma. We administered the combination of paclitaxel,
epirubicin and carboplatin to patients with metastatic or recurrent
carcinoma of the endometrium to evaluate its activity and to define its
toxicity.
Methods. Sixty-three consecutive patients were treated on an outpatient
basis with epirubicin 50 mg/m(2), followed by paclitaxel 150 mg/m(2),
administered intravenously over a 3-h period. Subsequently, the patients
received carboplatin at AUC of 5. The chemotherapy was repeated every 3
weeks with granulocyte colony-stimulating factor (G-CSF) support for a
maximum of six courses.
Results. Response was assessed among 56 eligible patients. Thirty-six
(63.2%) patients achieved objective clinical response (95% CI,
50.6-75.7%) including 14 (24.6%) complete and 22 (38.6%) partial
responses. The median duration of response was 7.9 months, and the
median times to progression and survival for all patients were 7.8 and
13.8 months, respectively. Grade 3 or 4 neutropenia occurred in 9
(15.5%) patients but only 3 episodes of neutropenic fever were
encountered. Grade 2 or 3 neurotoxicity was observed in 19% of
patients. Two patients died of sudden cardiac death 10 and 14 days after
the administration of the first chemotherapy cycle, respectively, but
these deaths were not clearly treatment related.
Conclusions. The combination of paclitaxel, epirubicin and carboplatin
with G-CSF support appears active in patients with metastatic or
recurrent carcinoma of the endometrium. (C) 2008 Elsevier Inc. All
rights reserved
A multicenter phase II study of docetaxel and vinorelbine in recurrent ovarian cancer: Activity in platinum-resistant, paclitaxel pretreated disease.
Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience
Two cycles of etoposide/cisplatin cured all patients with stage I testicular seminoma: Risk-adapted protocol of the Hellenic Cooperative Oncology Group
OBJECTIVES Adjuvant carboplatin is used as adjuvant therapy in Stage I
testicular seminoma. Although cure is the rule, relapses still occur,
especially in high-risk populations. We report the results of a
risk-adapted strategy by the Hellenic Cooperative Oncology Group.
METHODS From 1996 to 2003, 64 patients with Stage I seminoma and one of
two risk factors (maximal tumor diameter greater than 4 cm and/or age
younger than 34 years) were prospectively included in a protocol of
adjuvant chemotherapy. Treatment consisted of two 3-week courses of
etoposide 120 mg/m(2) and cisplatin 40 mg/m(2) for three consecutive
days with granulocyte colony-stimulating factor support.
RESULTS Of the 64 patients, 43 (67%) were younger than 34 years and 55
(86%) had a tumor diameter greater than 4 cm. Neutropenia and nausea
and vomiting were the most frequent grade 3 or 4 toxicities (16.5% and
9.5%, respectively), apart from alopecia. After a median follow-up of
60 months (range 7 to 118), no disease relapses have occurred. A
metachronous testicular carcinoma has been reported. One patient died of
causes unrelated to his disease.
CONCLUSIONS The results of our study have shown that two cycles of
etoposide and cisplatin is an effective and safe form of adjuvant
therapy for Stage I testicular seminoma. Risk factors can be used to
identify patients who could benefit from etoposide and cisplatin
treatment